secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001437749-24-031184
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar files provisional patent for novel radiopharmaceutical linkers and uPAR compositions
--------------------------------------------------------------------------------

- Filed provisional patent covering a family of linkers connecting radioisotopes to targeting agents, including uPAR antibody MNPR-101.
- Claims include composition of matter for linkers and uPAR targeting agents linked with therapeutic radioisotopes.
- New linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals.
- Linker family works with wide range of isotopes and targeting molecules (small molecules/peptides/antibodies).
- Management sees potential for licensing and development collaborations with industry partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031184/0001437749-24-031184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031184/mnpr20241014_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer